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ABSTRACT 
 
Human papillomavirus is the causative agent of the 2nd highest occurring cancer in 
women, cervical cancer, which is the result of expression of the E6 and E7 oncogenes. 
Here we challenged the dogma that the oncogenic protein E6 requires co-expression of 
E7 for malignant transformation of human keratinocytes using common HPV16 E6 
variants that are highly associated with cervical cancer: the Asian-American E6 variant 
(AAE6) and L83V variant of HPV16. The E6 variants containing the L83V amino acid 
mutation are more frequently detected in cervical cancer than the corresponding 
prototype HPV 16 as evidenced by independent epidemiological data. We set out to 
analyze in a cell culture study how these variants in the absence of E7 perform during 
vital steps of carcinogenesis and assessed their ability to immortalize and transform 
primary human foreskin keratinocytes (PHFKs). Their migration ability, a hallmark for 
invasiveness and/or metastasis, was also investigated. Immortalization capability was 
based on population doublings, number of passages, surpassing Mortality Stages 1 and 2, 
telomerase reverse transcriptase expression and the ability to overcome G1 arrest via p53 
degradation. Transformation and migration efficiency were analyzed by a combination of 
functional cell-based assays. For the first time, we observed that all E6 proteins alone 
were sufficient to immortalize PHFKs, with the AAE6 variant being the most proficient. 
The AAE6 variant protein alone also pushed PHFKs through transformation and 
significantly increased their migration ability over that of the PHFKs expressing L83V 
and E6 prototype proteins. Our findings are in line with epidemiological data that the 
AAE6 variant confers an increased risk over the prototype for cervical cancer as 
evidenced by a superior immortalization, transformation and metastasis potential.  
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LAY SUMMARY 
 
Faculty and students in the Department of Biology are bound together by a common 
interest in explaining the diversity of life, the fit between form and function, and the 
distribution and abundance of organisms. The purpose of the study undertaken here was 
to investigate the cancer-causing ability of different gene variants of human 
papillomavirus 16, a cause of many types of cancers today. The variations occur among 
the cancer-causing gene called E6 and the ones which were studied are the Asian-
American variant, the L83V variant, and the European prototype. This is a field which 
contains a large knowledge gap regarding the function of these variants and the resulting 
diversity in cervical cancer in the human population. Experiments revealing the ability of 
these different viral genes to immortalize and transform cells into a cancerous phenotype 
were completed and showed that the Asian-American gene variant was more powerful at 
completing these steps. This correlates with epidemiological studies which found this 
viral variant over the others in more cervical cancers. These results are of academic 
interest in that they assist in clarifying the function of these viral genes in the process of 
cancerous development, which in turn can be built upon for translational research. 
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1.0 INTRODUCTION 
 
In 2008 alone there were over 529,000 new cases of cervical cancer diagnosed, 
with most occurring in developing nations. Cervical cancer leads to the third highest 
mortality rate among all cancers in women, after breast and lung cancer (58). Etiological 
studies have shown a strong association between human papillomavirus (HPV) infection 
and cervical cancer (97). Hence it is important to improve our understanding of HPV-
induced carcinogenesis and appropriately elucidate the underlying molecular and cellular 
mechanisms involved. This will help develop improved screening procedures, better 
diagnostic and treatment approaches, as well as accelerate development of appropriate 
druggable targets. 
 
1.1 Human Papillomavirus 
 
Human Papillomavirus (HPV) is a double-stranded DNA virus belonging to the 
family Papillomaviridae. Members of this family infect the squamous epithelial cells of 
the skin and mucous membranes in humans. HPV infection is implicated in virtually all 
cervical cancers worldwide (97), making it the most important focus of studies regarding 
cervical cancer. 
 
There are over 100 types of HPV which can be divided into low- and high-risk 
categories based on their oncogenic potential. High-risk HPV types are prevalent in 
malignant tumours due to a better ability to immortalize and transform the host 
keratinocytes while low-risk HPV types are prevalent in benign lesions (68). HPV 16 is 
the most commonly known high-risk type (97), and within this type variation occurs in 
the genome sequence. The prevalence of these variants differs among populations (11, 
93), and the variants are distributed between the continents: European (E), Asian-
American (AA), African, and Asian (5) (Fig. 1 a). Epidemiological studies show 
differences in the ability of these variants to cause malignancies, and through these 
studies it has been suggested that the AA variant is most aggressive (2, 5, 12, 83, 91, 92, 
95). The HPV genome consists of three regions: the long control region (LCR), the upper 
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regulatory region, and the early (E) and late (L) gene region (Fig. 1 b). The LCR controls 
the production of viral proteins by regulating transcription of the early and late regions. 
The late region encodes structural proteins; L1 and L2 proteins are the major and minor 
capsid proteins, respectively. Both are expressed later during the infection in the upper 
epithelial layers during differentiation and they encapsulate the virus (96). The early 
region contains six open reading frames and is expressed in the basal layer. E1 and E2 
proteins are required for the initiation of viral genome replication. The E4 protein binds 
to proteins within the infected cells and contributes to the release of virions, and the E5 
protein has been shown to prevent apoptosis of DNA damaged cells (96). E6 and E7 are 
the major proteins involved in the carcinogenesis of the HPV virus. E6 is an oncoprotein 
that is found in the nucleus and cytoplasm of HPV infected cells (69, 96) and it interacts 
with p53, a tumour suppressor gene that is activated by DNA damage. p53 activation 
leads to cell cycle arrest and apoptosis of the damaged cells which assists in lowering the 
levels of possible mutations and therefore also the spread of viral infections (96). E6 
binds to p53 in a ternary complex with E6 Associated Protein (E6-AP) (78) and tags the 
p53 for degradation by ubiquitylation. This results in failure of p53‟s function which 
allows DNA replication to continue after damage has occurred (96). Because of this, E6 
can overcome cell cycle arrest which contributes to its oncogenic potential. E7 is another 
oncoprotein of HPV which can cooperate with E6 but can also act independently. It binds 
to the retinoblastoma protein (pRb) which releases E2F transcription factors. This leads 
to constitutive activation of E2F proteins which activate genes required for DNA 
synthesis. Therefore, by binding to pRb and effectively blocking it, E7 overcomes cell 
cycle arrest (96). Overall, both E6 and E7 function in surpassing growth arrest induced by 
DNA damage, and create chromosomal instability. Both of these conditions create the 
basis for the formation of a tumour mass. 
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Figure 1. The HPV genome. (A) The amino acid sequence of the European prototype E6 
oncoprotein with changes resulting in the Asian-American (AAE6), and L83V variants 
highlighted. The sequence has amino acids 1-151 and the AAE6 variant corresponds to 
the following changes: a glutamine (Q) to a histidine (H) change at the 14th amino acid, a 
histidine to a tyrosine (Y) change at the 78th amino acid, and a leucine (L) to a valine (V) 
change at the 83rd amino acid. Only the last change corresponds to the L83V variant. (B) 
This depicts the organization of the early and late genes of the HPV 16 genome. The 
early genes are E1, E2, E4, E5, E6 and E7. The late genes are L1 and L2. The Long 
Control Region (LCR) regulates the transcription of these genes. Taken from Beutner et 
al. (6). 
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About one-third of the known types of HPV infect the genital epithelia (26). The 
HPV viral genome begins its non-productive stage in the basal layer where it enters the 
cells. Here, it is established as a low copy number episome having its DNA replicated 
once per cell cycle. Afterward, it enters the productive stage in the suprabasal layer. Here, 
the DNA replication method switches from bidirectional theta replication to the rolling 
circle model which causes the DNA to reach a high copy number. The L1 and L2 capsid 
proteins are then synthesized and viral assembly occurs after which virions are released 
into the environment (Fig. 2) (22). Before HPV infection causes cervical cancer, HPV 
DNA must become integrated into the host genome. During this integration, the E2 gene 
expression is interrupted, and E6 and E7 expression is dysregulated (37). Cells containing 
integrated viral DNA proliferate more than cells containing episomal viral DNA (37), 
suggesting an increased potential for tumour formation, and therefore of cervical 
carcinoma. However, DNA integration only occurs after persistent infection from a single 
virus or multiple HPV types. Even after DNA integration neoplasias can be eliminated by 
the immune system so that only 0.8% of initial high-risk HPV infections develop into 
invasive cancer (96). One of the initial steps of the carcinogenesis process following 
infection with HPV 16 is cellular immortalization which was found to be mediated 
through the E6 and E7 oncogenes (32, 41, 56). 
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Figure 2. The expression of the various genes of HPV 16 during the infection 
process. In the basal layer, E1 and E2 initiate viral replication and the E6 and E7 
oncogenes are expressed. Once infected cells reach the suprabasal layer, E4 is expressed 
and readies the cell for virion release. Once in the squamous cells, L1 and L2 are 
expressed and viral particles can be released to the environment. Taken from Frazer et al 
(27).  
 
1.2 The Role of HPV16 E6 and E7 Oncogenes in Cellular Immortalization 
 
In 1989, several researchers published reports originally showing that the E6 and 
E7 oncogenes were the cause of cellular immortalization in HPV 16 positive primary 
human keratinocytes (32, 41, 56). These articles showed that when keratinocytes were 
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transfected with E6 or E7 oncogenes or both, it was necessary that E6 and E7 oncogenes 
cooperated to accomplish immortalization.  
 
Over the years, immortalization has been defined in numerous ways. During the 
time when Hawley-Nelson et al (32), Munger et al (56), and Kaur et al (41) published 
their papers, little was known about the causes of cell immortalization. As a result, these 
articles defined immortalization only as „extension of lifespan‟ and their experimental 
methods were suboptimal as gene technology at that time was rudimentary. In their 
studies, direct transfection was employed because amphotropic high titre virus 
technology was not yet developed for transducing primary human foreskin keratinocytes 
(PHFKs) (55) which would mimic conditions occurring in vivo. As more research was 
conducted through the years, the process of cell immortalization was partially resolved. 
In 1985, (29) Greider et al. discovered the enzyme telomerase, but it was not until 1992 
when Counter et al showed the link between telomerase expression and immortalization 
(15). This seminal report provided the foundation to further expand cell immortalization 
research. It is now known that the point when cells become immortalized is actually 
defined by an immortalization crisis, referred to as  mortality stage 2,  “M2” which takes 
place after a period of replicative senescence, mortality stage 1, “M1” (9, 74, 75, 77, 87). 
During M1, cells can remain viable for months then escape from this stage, resulting in 
extended lifespan which can be confused for immortalization. This can occur when cells 
express certain viral particles as in the case of high risk HPV type 16 infections (9). M2 
will occur once telomeres reach a critically short length and apoptosis is induced (9, 53, 
66). The process of escaping from this stage has been associated with the stabilization of 
telomere length through reactivation of telomerase (9, 53, 66), which was observed to be 
promoted by the E6 oncoprotein of HPV 16 (48, 54, 63, 77, 82). 
 
1.3 The Role of HPV16 E6 and E7 Oncogenes in Cellular Transformation 
 
Cellular transformation is another important part of the HPV-induced 
carcinogenic process. During this time, PHFKs attain a malignant phenotype which 
allows for formation of colonies that are resistant to harsh conditions, therefore producing 
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a microenvironment conducive to tumour growth (56). This can be seen when 
transformed cells successfully avoid detachment-induced death, or „anoikis‟ (28). When 
normal keratinocytes lose their ability to adhere to a substratum and to each other, 
terminal differentiation is induced (1) and cells commit to anoikis (28). Overcoming this 
could be supported by HPV 16 infection, whereby the E6 protein may counteract the pro-
apoptotic effects of p53 (71). Detachment conditions can be recreated in vitro through the 
use of semisolid medium (1). In addition, the ability of the cells to withstand serum 
starved conditions that can promote cell colony formation indicates the transformational 
ability of the cells (25). 
 
1.3.1 Invasion and Migration 
To complete the picture of carcinogenesis, invasion and migration ability must be 
assessed. Invasion of the tumour into the basement membrane is the first step in the 
metastasis cascade, the most deadly part of carcinogenesis. Following invasion, 
intravasation occurs when the primary tumour cells enter either lymphatic or blood 
microvessels. Here, they have access to nutrients and oxygen. If the cells enter blood 
microvessels, they may then be transported to distant sites throughout the body. 
However, this is a very hostile environment where cells may not survive. If the cells 
make it through the circulation, they can become trapped within vessels of other tissues 
and organs after which they must extravasate through interactions between vessel walls to 
form micrometastases. Eventually, certain micrometastases may acquire the ability to 
colonize the tissue/organ they have become trapped in, and a macrometastasis is formed. 
Once this occurs, the probability of developing more macrometastases from the first one 
is heightened since this secondary tumour has already acquired the ability to colonize 
tissues and organs (85). Before the metastasis cascade can proceed, the cells must 
undergo an epithelial-mesenchymal transition (EMT) which involves cells acquiring a 
mesenchymal phenotype in preparation for detachment from the epithelial sheets (85). 
One important gene that is down-regulated during this process is E-cadherin which 
mediates cell-cell attachment. It has been shown by Matthews et al. (51) that E6 gene 
expression down-regulates expression of E-cadherin as well, which potentially induces an 
EMT, suggesting this gene is an interesting subject for further study.  
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1.4 Mechanisms Causing Differences in Oncogenic Potential  
 
As previously mentioned, certain E6 oncogene variants are found more often than 
others in different populations (2, 5, 12, 83, 91, 92, 95) and through these studies, it is 
suggested that the AAE6 variant is more aggressive than others. In an effort to reveal the 
mechanisms behind the differing prevalence and oncogenic potential of these E6 
oncogene variants, metabolic pathways were studied. Carbonic anhydrase IX (CAIX) was 
chosen as an enzyme of interest since it is known to be regulated by hypoxia inducible 
factor 1 (HIF-1), a transcription factor affected by isocitrate dehydrogenase (IDH) (72). 
This was an enzyme found to be expressed differentially between the E6 gene variants in 
the presence of E7 (67). IDH is necessary for α-ketoglutarate production which is then 
used for hydroxylation of HIF-1α in normoxic conditions. Therefore, a decrease in IDH 
as was seen by Richard et al. (67) would result in an increase of HIF-1α and therefore 
HIF-1 (72). So, as a downstream gene in the HIF-1 pathway, CAIX is a viable target for 
observation as an indicator of enhanced metabolism and therefore oncogenic potential. 
 
1.5 Current Understanding of HPV 16-Induced Carcinogenesis 
 
Many researchers have followed the perception that E6 and E7 must work 
together to induce immortalization in human keratinocytes (18, 39, 43, 48, 49, 82), while 
Halbert et al. (31) observed that E7 alone was sufficient for immortalization. However, 
none of these articles were able to show a complete picture of immortalization as they 
relied only on one segment of the complex process as an indicator, such as extension of 
lifespan (31), inactivation of the retinoblastoma protein (39), or increased telomerase 
expression (18, 43, 48, 49, 82). Also, there has not been a study focused on the 
differences in immortalization and transformation ability between the different E6 
oncogene variants alone. 
 
Previously, the differences between AAE6 and prototype E6 gene variants along 
with E7 have been extensively studied through 2D-gel electrophoresis (67). The findings 
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have shown differences in expression of eight proteins involved in metabolic functions 
between the prototype E6 variant and variants containing the L83V mutation. These 
include enzymes of amino acid metabolism, the tri-carboxylic acid (TCA) cycle, and 
glycolytic pathways (67). These changes are some of what gives the AAE6 variant a clear 
advantage in in vitro immortalization and transformation over the prototype E6 because a 
higher metabolism indicates increased proliferative potential and survival (67). This 
opened the potential for further study into metabolic pathway changes between the 
different E6 oncogene variants.  
 
The purpose of this study was to observe the ability of E6 oncogene expression 
alone to immortalize and transform keratinocytes, and thereby increase the ability of the 
primary keratinocytes to invade and migrate into surrounding tissue. Clarifying the ability 
of the E6 gene alone to perform the initial steps in cervical cancer progression will allow 
for more focused future work on HPV 16-induced carcinogenesis.  
 
 
1.6 Hypotheses and Rationale 
 
1) The E6 oncogene alone can immortalize PHFKs through activation of telomerase 
mRNA synthesis and deactivation of p53 protein, irrespective of the HPV 16 
variant. 
 
Until now, no long-term study has been performed to challenge the concept that 
E6 and E7 are needed for immortalization, or to highlight the differences that may 
be seen between individual naturally occurring E6 variants without the help of E7. 
We propose a complete definition of the immortalization process using the 
keratinocyte model: PHFKs in culture surpassing M1 followed by a clear crisis 
(M2) and an increase in hTERT expression.  
 
2) Expression of the AAE6 oncogene alone will cause the PHFKs to show the first 
signs of malignant transformation.  
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Previously, the E6 and E7 oncogenes have been shown to be necessary for PHFK 
transformation (56) but the ability of the different E6 oncogene variants alone to 
transform PHFKs has not been observed, and the model used in the current study, 
PHFKs transduced by a viral particle, is more conducive to what is occurring in 
vivo than the model used by Munger et al. (56), PHFKs transfected with a 
plasmid. Results previously seen by our group show that the AAE6 oncogene in 
the presence of E7 formed colonies in semisolid medium (67), suggesting they are 
transformed.  
 
3) Expression of the AAE6 and L83V E6 oncogenes alone can increase PHFK‟s 
invasive and migratory ability compared to the E6 prototype-transduced PHFKs. 
 
Because metastatic tumours are usually found in vital organs, more than 90% of 
deaths from cancer are caused by these metastases (85). It is therefore extremely 
important to characterize the E6 oncogene‟s ability to increase invasion and 
migration capabilities of PHFKs. It has been shown previously in epidemiological 
studies (2, 95) that the HPV16 E6 oncogenes containing the L83V mutation in the 
presence of E7 are found more frequently than the E6 prototype in invasive 
carcinomas. In addition the AA variant has been found 20 times more often in 
cervical cancer than the prototype in the Americas (5). 
 
2.0 MATERIALS AND METHODS 
 
2.1 Cell Culture and Propagation 
 
2.1.1 Cell Lines 
All cultures were incubated at 37oC in a humidified atmosphere of 95% air and 
5% CO2.  Cells were grown in flasks of sizes 12.5 cm
2, 25 cm2, or 75 cm2. 
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Primary Human Epidermal Keratinocytes (PHFKs, Cell Applications Inc, San 
Diego CA, cat. # 102-05n) were cultured in Keratinocyte Growth Medium, Serum-Free 
(Cell Applications Inc, San Diego, CA, cat. # 131-500).  To passage these, the cells were 
incubated with trypsin which was neutralized with trypsin neutralizer (Cell Applications 
Inc, San Diego, CA, cat. # 080-100). To start the next 75 cm2 flask, 300,000 cells were 
seeded. 
 
Various other cancerous cell lines used as controls in a number of experiments 
were cultured as follows: A prostate cancer cell line DU145 (American Type Culture 
Collection (ATCC), Manassas VA, cat. # HTB-81) was cultured in Eagle‟s Minimum 
Essential Medium with Earle‟s Balanced Salt Solution (EMEM, Cedarlane, Burlington 
ON, cat. # 30-2003) and cervical cancer lines HeLa (HPV 18, ATCC, Manassas VA, cat. 
# CCL-2), and C33A (HPV negative, ATCC, Manassas VA, cat. # CRM-HTB-31) were 
cultured in Dulbecco‟s Minimum Essential Medium (DMEM, Sigma, St. Louis MO, cat. 
# D5796) supplemented with 10% fetal bovine serum (FBS, Sigma, St. Louis MO, cat. # 
F6178) and 1% antibiotics/antimycotics (Invitrogen, Carlsbad CA, cat. # 15240-062). To 
passage these, the cells were incubated with trypsin which was neutralized with media. A 
dilution of 1:10 was performed for the next starting flask. Phoenix cells used for viral 
transductions (a gift from Dr. Garry P. Nolan) were cultured following the same 
procedure as HeLa and C33A. 
 
2.1.2 Cryopreservation of Cells 
Left over cells were resuspended in 1 mL of freezing solution (10% dimethyl 
sulphoxide (DMSO, Sigma, St. Louis MO, cat. # 472301), and 90% respective culture 
medium).  Cells were put into cryotubes then into an isopropanol-containing freezing unit 
overnight in the -80oC freezer.  The cells were then transferred to liquid nitrogen storage. 
 
2.1.3 Thawing Cells 
The cells were thawed from liquid nitrogen storage in a 37oC water bath.  All 
contents of the cryotube were added to 9 mL respective culture medium and the solution 
was centrifuged for 5 minutes at 25 x g (Beckman GS-6KR Centrifuge, Mississauga, 
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ON).  The supernatant was aspirated and the cell pellet was resuspended in the 
appropriate culture medium and transferred to a flask. 
 
2.1.4 Protein Extraction for Western Blotting 
After storage at -80oC the cell pellet was washed with 1 X Dulbecco‟s Phosphate 
Buffered Saline (PBS, Invitrogen, Carlsbad CA, cat. # 14190) and resuspended in 110 µL 
of lysis buffer (1 mL nuclei buffer (0.25 M Sucrose, 0.2 M NaCl, 10 mM Tris-HCl, 2 
mM MgCl2, 1 mM CaCl2, 1% TritonX-100, and water to 1 L), 10 µL 
phenylmethylsulfonyl fluoride (PMSF, Sigma, St. Louis MO, cat. # P7626), and 1 µL 
protease inhibitor cocktail (Sigma, St. Louis MO, cat. # P8340)), and left on ice for 20 
minutes.  The solutions were centrifuged for 1 minute at 16,000 x g (Eppendorf 
Centrifuge 5415C, Mississauga, ON) to remove cell debris and the supernatant was 
obtained.  A Bradford assay was done using Bio-Rad Protein Assay (Bio-Rad, Hercules 
CA, cat. # 500-0006) to determine the protein concentrations of the samples for further 
use in western blotting. 
 
2.2 Transformation 
 
2.2.1 Selective Agar Plates and LB Broth 
LB agar tablets (Sigma, St. Louis MO, cat. # L7025) were mixed with double 
distilled water (DDW) for 2 minutes and autoclaved on liquid cycle (20 minutes at 
121oC).  The agar was cooled to 54oC using a water bath and ampicillin (Sigma, St. Louis 
MO, cat. # A9393) was added to a concentration of 100 µg/mL agar.  Plates were poured 
in the tissue culture hood and allowed to dry before use in growing up bacteria for 
plasmid DNA amplification.  Unused plates were stored at 4oC.  
 
LB broth tablets (Sigma, St. Louis MO, cat. # L7275) were mixed with DDW for 
2 minutes and autoclaved on the liquid cycle (20 minutes at 121oC).  Extra broth was 
stored at room temperature. 
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2.2.2 Transformation of E. coli Cells 
In order to generate E6 and E7 viral particles, 5-alpha competent E. coli cells 
(New England BioLabs, Ipswich, MA, USA cat. # C2992H) were transformed with 
plasmid DNA carrying either E6 or E7 gene inserts. Briefly, 1µL of plasmid DNA (E6 
prototype, AAE6 variant, pLxSN (empty vector), L83V, or green fluorescent protein 
(GFP)) was added to each tube of E. coli cells and mixed.  Each mixture was put on ice 
for 30 minutes then heat shocked at 42oC in a water bath for 30 seconds to facilitate the 
entry of the plasmid into the bacteria.  They were then placed on ice for another 5 
minutes and 950µL room temperature SOC medium (New England BioLabs, Ipswich 
MA) was added to each.  The mixtures were put in a shaker at 37oC for 60 minutes at 250 
rpm, and selection plates were warmed to 37oC at this time.  75 µL of each mixture was 
spread onto one selection plate each and incubated overnight at 37oC in the bacterial 
incubator.  The bacteria that grew should contain the plasmid due to the selection 
characteristics of the plate (the plate contained ampicillin, the plasmid contained an 
ampicillin resistant gene). This was later confirmed by expression of the E6 and E7 
oncogenes through RT-PCR. 
 
The next day, 5mL LB broth was aliquoted into a 15 mL falcon tube for each 
construct and ampicillin was added to a concentration of 100 µg/mL.  A single colony 
from each selection plate was selected and added to the broth.  The cell suspension was 
put into the shaker at 37oC and shaken at 300 rpm for 8 hours to allow the bacteria to 
grow, therefore allowing the plasmid to multiply. 
 
After 8 hours, 500 µL from each cell suspension was added to 250 mL LB broth 
containing 100 µg/mL ampicillin in a 1L flask.  The new cell suspensions were put into 
the shaker overnight at 37oC and 300 rpm.  The next day, the suspensions were divided 
among 50mL falcon tubes and centrifuged at 6000 x g (Beckman Coulter Allegra™ 25R 
Centrifuge) for 15 minutes.  The supernatants were decanted and the pellets were stored 
at -20oC. 
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2.3 Maxi Prep 
 
A maxi prep was performed on the pellets of the overnight growth bacteria to 
remove the plasmids from the E. coli cells.  This was done using the EndoFree® Plasmid 
Maxi Kit (Qiagen, Hilden Germany, cat. # 12362), and was completed according to the 
manufacturer‟s protocol without any changes.  DNA concentrations were read using a 
Synergy 4 plate reader.  The final product of each construct was stored at -20oC. 
 
2.4 Retroviral Infection 
 
2.4.1 Calcium Phosphate Transduction Method 
To obtain viral particles for infection of keratinocytes, a calcium phosphate 
transfection was performed on Phoenix cells in a 75 cm2 flask using a kit from Clontech 
(Mountain View, CA). First, 5 mL fresh DMEM with serum and 5 µl chloroquin was 
added to each flask.  Next, DNA mixtures were made up for each variant comprised of 10 
µg DNA, water making the solution up to 438 µl, and 62 µl of calcium solution (0.248 M 
final concentration). The mixture for each variant was added drop-wise to 500 µl 
HEPES-buffered saline, mixed, and was then added to the cells drop-wise.  The flasks 
were then incubated at 37oC, 95% oxygen, 5% CO2 for 10 hours, washed with 5 mL 1 x 
PBS, and 10mL fresh medium was added. After 24 hours, the cells were washed again 
with 1 x PBS and 5mL fresh media was added. Another 24 hours later, the media was 
drawn through a syringe with a 0.2 µm filter and kept at -80oC. 
 
2.4.2 Transfection Efficiency Check 
The flask containing Phoenix cells transfected with GFP plasmid DNA was 
observed under a Zeiss fluorescent microscope.  Pictures were taken at a 10X objective 
with an exposure time of 10 milliseconds for halogen light and 50 ms for fluorescence 
(longer exposure to correct for the difference between what is seen under the microscope 
and what is seen on the computer screen).  The amount of cells seen with the halogen 
light was counted as well as the amount of cells seen containing fluorescence and a 
transfection efficiency percentage was obtained.  
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2.4.3 Transduction 
In order to obtain a biological model of HPV 16 infected keratinocytes, PHFKs 
were grown to passage three in 12.5 cm2 flasks. There were three flasks for each 
construct, one for a selection control, and one to continue the untransduced PHFKs. 
These were seeded at 0.75x105 cells per flask, and the transduction was performed when 
the cells reached 60-70% confluency. The viral supernatants from the transfected Phoenix 
cells (55) were used for the following constructs: prototype E6, AAE6, L83V, E7, and 
pLxSN. E7 viral supernatant was obtained from Phoenix cells transfected with E7 DNA 
obtained from a personal contact of Dr. Zehbe. In each flask, the medium was aspirated 
and 2mL of the respective viral supernatant was added in the presence of polybrene (a 
cationic polymer used to increase the transduction efficiency, 1 µg/mL viral supernatant). 
A co-transduction was also performed using 1 mL of E7 supernatant and 1 mL of 
prototype E6 supernatant in three flasks to create E6E7. The flasks were incubated at 
37°C and 5% CO2 atmosphere for 3 hours, after which Keratinocyte Growth Medium 
was added 1:1. This was done to avoid supernatant serum-induced differentiation from 
the DMEM of the viral supernatant. The flasks were incubated for another 3 hours and 
the media mixture was aspirated. 5 mL of Keratinocyte Growth Medium was added back 
to the flasks and the cells were placed back into the incubator. 
 
2.4.4 Selection 
The day after transduction, a selection was performed to ensure all cells growing 
contained the viral constructs. The media was replaced in each flask with Keratinocyte 
Growth Medium containing 100 µg/mL gentamicin (G418, Roche Applied Science, 
Laval QC, cat. # 11059467001). The cells were incubated at 37°C and 5% CO2 
atmosphere for 48 hours, after which the media was replaced with more Keratinocyte 
Growth Medium containing 100 µg/mL G418. This was continued for 4 days, and then 
the medium was changed to medium containing 50 µg/mL G418 for a maintenance 
selection. This was continued for one week after which the medium was changed to 
regular medium without G418 to end the selection.  
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2.5 Analysis of Cellular Immortalization 
 
2.5.1 DNA and RNA Extraction 
For future PCR and quantitative real time (qRT-) PCR, DNA and RNA were 
extracted from the infected cells at passages 6, 16 and 30. DNA was extracted following 
the Animal Blood (Spin-Column) protocol in the DNeasy® Blood and Tissue Kit 
(Qiagen, Hilden Germany, cat. # 69504) and the concentration was measured using a 
Synergy 4 plate reader after which the DNA was stored at -20oC. RNA was extracted 
using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems, Carlsbad CA, cat. # 
KIT0204). The quality and purity was assessed using the Bio-Rad Experion Automated 
Electrophoresis system with the StdSens Analysis Kit (Bio-Rad, Hercules CA, cat. # 700-
7111) and the quantity was measured using a Synergy 4 plate reader after which the RNA 
was stored at -80oC. 
 
2.5.2 Reverse transcription 
For future qRT-PCR, the RNA was reverse-transcribed using the High Capacity 
cDNA Archive kit (Applied Biosystems, Carlsbad CA). Samples were made up to 30 µl 
with nuclease-free water and 30 µl master mix (containing 10x RT buffer, 10x primers, 
25x dNTPs, and multiscribe) was added. The parameters for the thermocycler were 25oC 
for 10 minutes, 37oC for two hours, and 85oC for 5 minutes.  
 
2.5.3 PCR and qRT-PCR 
In order to ensure E6 and E7 oncogenes were being expressed in the infected 
PHFKs, PCR and qRT-PCR were performed. Briefly, for PCR, 100 ng DNA was used 
along with the master mix containing 1x PCR buffer, 1 mM MgCl2, 200 µM dNTPs, 
0.5µM of forward and reverse primer, and 1unit of Taq polymerase. The thermocycler 
parameters were 40 cycles of 94oC for 1 minute, 55oC for 1 minute, 72oC for 2 minutes 
and a final extension at 72oC for 7 minutes. The resulting amplified DNA was imaged on 
a 1.5% agarose gel. For qRT-PCR, 150 ng of cDNA was mixed with 45 µl TaqMan 
master mix, 4.5 µl of the gene assay (either hTERT, HPRT1, E6, or E7; Applied 
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Biosystems) and nuclease-free water to make it up to 90 µl. Triplicates of 25 µl each 
were pipetted into a 96-well plate and analyzed by a 7500 ABI cycler. 
 
2.5.4 Cell Cycle Analysis 
In order to determine if the infected cells could overcome induced cell cycle 
arrest, actinomycin D (AD, Sigma, St. Louis MO, cat. # A9415) was added to one of two 
dishes of cells at a concentration of 0.5 nM to induce p53 expression through DNA 
damage (24). To the other dish, 100% DMSO was added as a control. The cells were 
incubated for 24 hours then were harvested and washed once with 1xPBS and were 
resuspended in 200 µL of 1xPBS. While vortexing the cell suspension, 1.8mL of ice cold 
ethanol (70%) was added drop-wise to fix the cells. They were stored at 4oC for at least 4 
hours, or until flow cytometry could be done. This was completed at passage 6, 16 and 30 
and analysis was performed using the CellQuest Pro program with the FACS flow 
cytometer. Briefly, the cells were spun down at 25 x g (Beckman GS-6KR Centrifuge) 
for 5 minutes, and the ethanol was decanted. The pellet was then washed in 1xPBS after 
which the supernatant was aspirated and each pellet was resuspended in 0.6mL of the 
following mixture: 100 µL of 10% Triton X-100, 100 µL of RNase A (Qiagen, Hilden 
Germany, cat. # 19101), 200 µL of 1 mg/mL propidium iodide, and 9.75 mL of 1xPBS. 
The standard flow cytometry protocol was followed from here on. To analyze, peaks 
representing the different cell cycle phases of G1, S, and G2/M were gated within the 
CellQuest Pro program for the DMSO-treated samples. For each corresponding AD-
treated sample, the gates were not adjusted. The percentage of cells in each of the G1 and 
S phases in the AD-treated samples was standardized to the percentage of cells in each of 
those phases in the DMSO-treated cells (AD:DMSO). A G1:S ratio was then made based 
on AD:DMSO ratio for each phase.   
 
2.5.5 Inducing Anoikis 
To observe if the infected PHFKs were transformed, anoikis was induced using 
semisolid medium. To make semisolid medium, 3.37 g of methylcellulose (Sigma, St. 
Louis MO, cat. # M0512) was autoclaved for 20 minutes with a magnetic stir bar. 200 
mL serum-free medium (Ham‟s F12 (Invitrogen, Carlsbad CA, cat. # 21700-075) and 
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DMEM at a ratio of 3:1 as well as calcium at a final concentration of 0.66 mM) was 
made up and half of it was heated to 60oC. The heated medium was then added to the 
autoclaved methylcellulose and mixed for 20 minutes at room temperature. Next, the rest 
of the medium was added and stirred at 4oC for 1 hour. The medium was then aliquoted 
into 50 mL falcon tubes and centrifuged for 90 minutes at 15,000 x g (Beckman Coulter 
Allegra™ 25R Centrifuge) to remove non-dissolved methylcellulose fibres. Once the 
cells reached passage 6 (subcultured six times after transduction), 200,000 cells were 
seeded into 15mL falcon tubes (in triplicates for each flask) and resuspended in semisolid 
medium at a density of 1x106 cells/mL. 100,000 cells were also seeded into each well of a 
6 well plate as a negative control (one for each flask). The tubes and plate were incubated 
at 37°C and 5% CO2 atmosphere for 24 hours, after which the plate wells were overlaid 
with semisolid medium and incubated for another 24 hours. The tubes were spun down 
for 5 minutes at 25 x g (Beckman GS-6KR Centrifuge) and the medium aspirated. The 
pellets were washed three times with 1xPBS, once with regular Keratinocyte Growth 
Medium, and then twice more in 1xPBS. The pellets were stored at -20oC until flow 
cytometry could be done. After the control cells had incubated for 24 hours, they were 
harvested and processed following the same method that was done for the tubes. This was 
repeated when the cells reached passages 16 and 30. To analyze the effect of the 
semisolid medium on the cells, flow cytometry was performed. Briefly, pellets were 
resuspended in 1x106 cells/mL binding buffer and moved to 5 mL round bottom tubes. 
Each volume was split in two for technical replicates. A portion of each control was 
combined for an unstained sample to calibrate the cytometer. From an Annexin V-FITC 
kit (Sigma, St. Louis MO, cat. # APOAF-50TST), 2.5 µL of annexin V-FITC reagent and 
5 µL of propidium iodide was added to each sample and they were incubated in the dark 
for 10 minutes at room temperature. The suspension was analyzed by flow cytometry 
using the CellQuest Pro program on a FACSCalibur flow cytometer (Becton Dickinson). 
To analyze, the percentage of cells in each quadrant is observed. The top right quadrant 
contains cells that are annexin V-FITC positive and propidium iodide positive, signifying 
that they are dead. The lower right quadrant contains cells that are annexin V-FITC 
positive and propidium iodide negative, which shows that they are in early apoptosis. The 
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lower left quadrant contains cells that are annexin V-FITC negative, and propidium 
iodide negative, meaning that they are alive.  
 
2.6 Protein Expression Analysis 
 
2.6.1 Gel Electrophoresis 
SDS-PAGE gels were made for protein analysis.  First, the separating gel was 
made at various concentrations depending on the protein of interest.  This mixture 
contained 53.5% DDW, 0.375 M Tris - HCl (pH 8.8), 8% acrylamide (Bio-Rad, Hercules 
CA, cat. # 161-0146), 0.1% sodium dodecyl sulphate (SDS), 0.06% ammonium 
persulfate (APS, Sigma, St. Louis MO, cat. # A9164), and 0.1% TEMED (Sigma, St. 
Louis MO, cat. # T7024).  This was allowed to polymerize for 15 minutes.  The stacking 
gel was made which contained 63.6% DDW, 0.126 M Tris - HCl (pH 6.8), 4% 
acrylamide, 0.1% SDS, 0.08% APS, and TEMED.  This was added and the gel combs 
were put in the gel to make the wells for the samples.  The gel was allowed to polymerize 
for 30 minutes.  Once the gel had polymerized, samples containing SDS were prepared.  
Each sample was boiled for 5 minutes and the standard was boiled for 2 minutes (Bio-
Rad Prestained SDS-PAGE standards Low Range, or Precision Plus Streptactin –HRP 
conjugate, Hercules CA, cat. # 161-0305 or 161-0380).  These were then spun down for 
30 seconds at 16,000 x g (Eppendorf Centrifuge 5415C). A noted amount of protein was 
loaded into each well based on the known concentrations of each sample.  The gel was 
run at 100V in 1X running buffer (144 g glycine, 30.3 g Tris Base, 50 mL 10% SDS into 
1 L of DDW, then 100 mL of this into 900 mL of DDW) until the samples ran into the 
separating gel, then the voltage was turned up to 120V.  Once the samples had run to the 
bottom of the gel, indicated once the dye front had disappeared, the electrophoresis was 
stopped.  
 
2.6.2 Western Blotting 
The gel was transferred to PVDF membrane in 1X transfer buffer.  This was done 
for 1 hour at 100V.  The membrane was cut to size and soaked for 10 minutes in 1X Tris-
Buffered Saline with Tween 20 (TBST), and then blocked in an appropriate percentage of 
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milk for 1 hour at room temperature.  The membrane was then put into primary antibody 
solution (Antibody diluted in milk. Used CAIX (1:5000 dilution, ab15086, Abcam) and 
E-cadherin (1:200 dilution, M3612, DAKO)) overnight with agitation at 4oC.  The next 
day, the membrane was washed 4 times for 10 minutes each in 1X TBST.  It was then put 
into secondary antibody solution (made in milk, antibody specific to primary) for 1 hour 
at room temperature.  Afterwards the membrane was washed again 4 times for 10 
minutes each time in 1X TBST.  Chemiluminescence was done with Western Lightning 
Plus-ECL (PerkinElmer, Inc.) solutions.  One mL of each of the two solutions was mixed 
together and was put onto the membrane for 2 minutes. Pictures were then taken using 
the Biospectrum 410® Imaging System (UVP).   
 
2.6.3 Normalization and Densitometry 
The housekeeping gene actin was used as a loading control to normalize the 
results.  Each western blot was stripped of its previous primary/secondary antibody 
complex by incubation with stripping solution (7.507 g glycine and 5.844 g NaCl, into 1 
L of DDW (pH 2.2) and autoclaved for 20 minutes at 121oC) for 1.5 hours.  Each blot 
was then probed with actin primary antibody (actin goat polyclonal IgG. Santa Cruz 
Biotechnology, Inc.) at a concentration of 1:1000 in 5% milk, and a secondary antibody 
(Peroxidase-conjugated AffiniPure Donkey Anti-Goat IgG. Jackson ImmunoResearch 
Laboratories, Inc.) at a concentration of 1:2000 in 5% milk.  The density of the actin and 
the protein bands were calculated for each sample using the UVP VisionWorks®LS 
Analysis Software.  These densities were compared as ratios and these ratios were then 
compared between samples. 
 
2.7 Transformation Study 
 
2.7.1 Clonogenic Assays 
High passage keratinocyte cultures (passage 65) containing the various E6 genes, 
as well as negative and positive control cells (parental PHFKs from passage 3 and HeLa 
cells, respectively), were assessed for their ability to form colonies in the presence of 
basement membrane proteins mimicking in vivo conditions through a modified 
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clonogenic assay described by (25). Briefly, 6-well plates were immobilized with and 
without 20 µg/mL Matrigel (BD Biosciences) and blocked with 1 % Bovine Serum 
Albumin (BSA) to prevent non-specific binding of cells to the substratum. Cells were 
seeded on the plates and grown for 11 days in serum-free DME/F12 media. The cells 
were replenished with fresh serum-free media every third day and on the eleventh day 
fixed with cold methanol and stained with 0.1 % Crystal violet Gram Stain (Sigma 
Aldrich) and imaged under low magnification. Colonies were observed and categorized 
into scattered, closed, or mixed types. 
 
2.7.2 Adhesion and Viability Assays 
To determine whether the basement membrane proteins promote cell adhesion 
capacity, an adhesion assay was performed. Briefly, 96-well plates were immobilized 
with different concentrations of matrigel (0 µg/mL, 5 µg/mL, 10 µg/mL, 20 µg/mL, and 
40 µg/mL) in technical replicates of 4, and blocked with 1% BSA for at least 10 minutes. 
About 100,000 cells were seeded per well, after which plates were incubated at 37oC for 
40 minutes. The cells were washed with Serum free DME/F12 until cells in the BSA 
wells stopped detaching. The cells were fixed within the wells using ice cold methanol 
for 10 minutes at -20oC. Methanol was aspirated and residual methanol was washed away 
with 1xPBS. The PBS was aspirated and cells were stained with 0.1% crystal violet Gram 
Stain. Filtered 2% SDS was added to all wells and the plates were incubated with 
agitation at room temperature for 30 minutes, after which absorbance readings at 550 nm 
were taken using the PowerWave XS plate reader (BioTek, Vermont, USA). In order to 
determine if the matrigel affects the cell proliferation a resazurin based fluorimetric assay 
(R & D Systems, Minnesota, USA) was performed. After the 96-well plates were 
immobilized with matrigel as described above, 4000 cells were seeded per well and 
allowed to grow in their normal growth medium until BSA wells reached a confluence of 
80%. Resazurin solution was added to each well as described by the manufacturer‟s 
protocol and plates were incubated at 37oC for 2 hours after which the plates were 
incubated with agitation in the dark at room temperature for 20 minutes. The fluorescence 
intensities were measured using the FLx800 plate reader at excitation of 540 nm and 
emission of 590 nm.  
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2.8 Migration Study 
 
2.8.1 Invasion and Migration Assays 
High passage (passage 70) keratinocyte cultures containing the various E6 genes, 
as well as negative and positive controls (PHFKs, HeLa and L83V/E7 and prototype 
E6/E7 and AAE6/E7, respectively) were assessed for their ability to migrate through a 
porous membrane. A CytoSelect™ 24-well Cell Haptotaxis Assay (Cell Biolabs) coated 
with collagen I was used for this study. Ten percent FBS in KGM was added to the 
bottom chamber of two out of three wells per variant. The third well was left without 
FBS to control for random migration. Each variant was seeded at 150 000 cells per insert 
and the plate was incubated at 37oC for 16 hours, the time chosen by observing what 
other groups have used in similar experiments (3, 10, 33, 64, 81). Migratory cells were 
stained, and imaged using an inverted microscope at 200X magnification. Three fields 
per insert were imaged, the stain was extracted and the absorbance reading at 560nm was 
taken using the PowerWave XS plate reader (BioTek, Vermont, USA).  
 
 
2.9 Statistics 
 
All statistical analyses were performed using open-source statistical software 
called R (version 2.12.1, R Development Core Team. 2008. R: A language and 
environment for statistical computing. R Foundation for Statistical Computing, Vienna, 
Austria. URL http://www.R-project.org). All data were tested for normality and 
homogeneity of variances using a Shapiro-Wilks test and a Bartlett‟s test, respectively, 
before choosing a suitable parametric or non-parametric statistical test. A resulting p-
value of less than 0.05 was considered to be significant. Parametric data sets were 
analysed using student‟s t tests and one and two-way ANOVAs followed by a post-hoc 
such as a Tukey HSD. Non-parametric data sets were analysed using two-way ANOVAs 
or one-way Kruskal Wallis ANOVA followed by a Nemenyi‟s post hoc, and Friedman‟s 
tests followed by a pairwise comparison using a Wilcoxon signed rank test with a 
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Bonferroni adjustment. Cell population doublings were calculated based on the method 
described by Willey et al. (86). 
 
3.0 RESULTS 
 
In the current study, three HPV16 E6 oncogene variants have been characterized 
with respect to their ability to immortalize, transform, and increase invasion/migration 
ability in PHFKs. A similar study was previously completed by our group (data not 
published, manuscript submitted) and the results from the current study were used to 
confirm the results seen before. The previous study had transduced PHFKs grown until 
passage 60 whereas the current study examined preliminary signs that PHFKs from a 
separate donor were exhibiting characteristics seen in the first donor through growth until 
passage 30. Transduced PHFKs grown until passage 60 were considered fully 
immortalized and were therefore used to test other parameters to assess the E6 
oncogene‟s role in cellular transformation and induction of invasion and migration. 
 
3.1 The E6 oncoprotein alone is sufficient for PHFK lifespan extension and escape from 
the immortalization crisis 
 
3.1.1 Confirmation of E6 Oncogene Expression 
Conventional and qRT-PCR both confirmed the presence and expression of the 
E6 genes in each variant at checkpoints of passages 6, 16 and 30 (Fig. 3). All E6 variants 
were devoid of any E7 expression, E7 was devoid of any E6 expression and pLXSN and 
parental PHFKs were clear of any E6 or E7 expression. 
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population doublings while by passage 30, the AAE6, prototype E6 and L83V variants 
completed 55, 50, and 55 doublings, respectively. The positive control E6E7 completed 
71 doublings while E7 completed 65 (Fig. 4 b). The population doubling times were 
calculated based on a method described by Willey et al. (86): AAE6 reached passage 30 
in 126 days, prototype E6 in 138 days and L83V in 155 days with a difference in 
population doubling time being 67.54 hours ± 24.67 (AAE6), 82.89 hours ± 34.02 (E6 
prototype), and 80.73 hours ± 37.17 (L83V). The positive control of E6E7 took 130 days 
with a population doubling time of 51.42 hours ± 18.21 while E7 took 168 days with a 
population doubling time of 90.95 ± 90.34 (Table 1). The positive control E6E7 had 
significantly more population doublings than all E6 variants (p<0.05), and also had 
significantly shorter population doubling times (p<0.05) compared to prototype E6 and 
L83V. Therefore, the AAE6 population doubling time is comparable to the positive 
control. The differences seen here between the E6 oncogene variants could be attributed 
to variations in metabolic enzymes as suggested by Richard et al. (67). To test this 
notion, we performed western blotting on high passage transduced PHFKs to examine 
CAIX expression levels. 
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Table 1. Population doubling time in hours for transduced primary human keratinocytes. PHFKs containing the E6 oncogene 
variants were passaged up to 30 times. The population doubling times in hours were calculated using a standard formula (3.32(log Nt - 
log No) = tf) where Nt is the number of cells counted and No is the number of cells plated. E6E7 has significantly lower population 
doubling time compared to prototype E6 and L83V (p<0.05, one-way ANOVA, n=27). 
 
 
Passage 6-16 Passage 17-30 Passage 6-30 
Variant Doubling Time (h) Passages (d) Doubling Time (h) Passages (d) Doubling Time (h) Passages (d) 
AAE6 73.63 ± 28.82 57 62.76 ± 20.71 69 67.54 ± 24.67 126 
Prototype E6 83.26 ± 38.01 60 82.60 ± 32.01 78 82.89 ± 34.02 138 
L83V 87.95 ± 41.91 64 75.06 ± 33.48 91 80.73 ± 37.17 155 
E6E7 61.79 ± 15.64 70 43.27 ± 16.17 60 51.42 ± 18.21 130 
E7 97.55 ± 117.18 77 85.77 ± 66.61 91 90.95 ± 90.34 168 
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3.1.3 The E6 variants activate CAIX at different expression levels to enhance 
carcinogenesis 
In order to determine a mechanism behind the differences seen in oncogenic 
potential in the different E6 oncogene variants, the protein expression level of CAIX in 
the E6 transduced PHFKs was investigated through western blotting. CAIX is a 
metalloenzyme which is known to function in pH regulation and cellular adhesion. It 
regulates pH by converting carbon dioxide to bicarbonate facilitating the transportation of 
the bicarbonate from extracellular to intracellular spaces. This is necessary for the cells to 
survive acidic pH conditions that are formed in a typical tumour microenvironment by 
neutralizing the intracellular space (60). The enzyme controls cell adhesion through its 
proteoglycan domain containing specific amino acid sequences that allow it to mediate 
cell attachment to non-adhesive solid support. It is known to be upregulated in many 
cancers and is indicative of a poor patient prognosis (60). CAIX expression was highest 
in AAE6 over the other variants and HeLa cells but this was not significant (Fig. 5 a). 
The CAIX expression differences were also studied in the AAE6 and prototype E6 
variants in the presence of E7 since these variants were the focus of the study by Richard 
et al. (67). It was found that the AAE6/E7 had significantly increased expression of 
CAIX over the prototype E6/E7 variant (p<0.001) (Fig. 5 b), suggesting that E7 is 
necessary for stabilization of CAIX expression and also that CAIX expression is one 
means by which the oncogenic potential in the AAE6 variant is increased over the other 
variants.                     
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under normal cellular conditions, p53 is elevated which in turn activates p21. This leads 
to a downregulation of cyclin-dependent kinases that is essential for cell cycle 
progression resulting in G1 arrest (34). In the absence of p53, it has been shown that cells 
bypass M1 (88). Since E6 is known to abolish p53 activity, its presence in PHFKs should 
be enough to bypass cell cycle arrest and consequently, M1. To test this notion, 
actinomycin D was used to induce DNA damage through strand breaks by interfering 
with cellular topoisomerase activity (24). This results in an increased p53 expression, 
which will lead to G1 arrest (40). The PHFKs containing the E6 variants were expected 
to block this induced p53 activity, and this cell cycle stage was analyzed by flow 
cytometry. G1:S ratios were calculated by comparing the number of cells in G1 phase 
with the number of cells in S phase. The ratios approaching or below one were 
considered to reflect cells overcoming the cell cycle arrest. Already at passage 6, it was 
observed that expression of any of the E6 proteins significantly contributed to cells‟ 
ability to overcome G1 arrest when compared to PHFKs (p<0.01) (Table 2). E7-
expressing PHFKs were only able to overcome arrest once in passage 30. This shows that 
the E6 oncoprotein was functional and the transduced PHFKs were overcoming M1. 
 
 
 
 
 
 
 
 
 
Table 2. Cell cycle stage analysis of transduced primary human keratinocytes. Flow 
cytometry was performed to observe the effect of the E6 oncogene on induced cell cycle 
arrest. PHFKs containing the E6 oncogene variants were exposed to actinomycin D and a 
G1:S ratio was calculated. This experiment showed that the E6 oncogene expression 
resulted in overcoming G1 cell cycle arrest, leading to a significantly higher number of 
cells in S phase when compared to PHFKs (p<0.01, two-way ANOVA, n=3). 
 
G1:S 
Variant Passage 6  Passage 16  Passage 30  
AAE6  0.88 0.80 0.85 
Prototype E6  0.95 0.92 0.83 
L83V  0.88 1.02 0.94 
E6E7 1.05 1.01 0.99 
E7  2.32 1.34 0.89 
PHFK  2.60 N/A N/A 
pLXSN  2.60 N/A N/A 
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3.1.5 Overcoming Mortality Stage 2 Leading to Immortalization 
Once keratinocytes bypass M1, they are characterized by an extension of lifespan 
after which an immortalization crisis, M2 ensues (73, 87). All E6 PHFK cultures 
exhibited some level of crisis during the culture period from which the immortalized 
subpopulation emerged. AAE6 had a shorter major crisis time (100 h) compared to the 
prototype E6 (175 h) and L83V (200 h) variants. E7-expressing PHFKs had two major 
crises, each being much longer than any E6 variant crises (450 h and 275 h, respectively), 
while the positive control E6E7 had one crisis of 100 h (Fig. 6). Overcoming this stage 
has been attributed to combating telomere shortening. In normal cells, telomeres are 
constantly shortened until they reach a critical length and in the process important 
chromosomal DNA is lost, leading to cell death. Immortalized cells have ways to 
overcome this condition through transient expression of telomerase which acts to restore 
telomere length (29). It is composed of a catalytic subunit termed telomerase reverse 
transcriptase (hTERT) and a template RNA. This enzyme is present in normal cells but is 
inactive. However, it is still detectable at very low levels (14, 30, 94). E6 has been shown 
to induce telomerase activity through an increase in hTERT transcription in 
keratinocytes, a hallmark for immortalization (44, 48, 54, 57, 63, 77, 82). To further 
assess immortalization status of the variants, qRT-PCR for hTERT was performed on 
transduced PHFKs as well as control PHFKs. The expression of the telomerase subunit 
hTERT was standardized to hypoxanthine phosphoribosyltransferase 1 (HPRT1) 
expression in the E6 PHFK cultures as previous results indicate HPRT1 expression is 
unaffected by HPV infection (16). As expected, it was observed that as the passage 
number increased from 16 to 30, hTERT expression steadily increased in a time-
dependent manner (Fig. 7) showing that this mechanism for immortalization was 
consistently being up-regulated. Once at passage 30, hTERT expression was highest in all 
E6 variants as well as E6E7. E7 expression did not induce hTERT expression, leading to 
the conclusion that E7 oncogene expression cannot immortalize PHFKs. 
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Figure 6. Average population doubling time in hours per passage in primary human 
keratinocytes transduced with E6 oncogene variants. To highlight the different points 
of immortalization crisis (M2) within each culture, doubling time in hours was plotted 
against passage number for each variant from each donor. An extreme increase in 
doubling time suggests a point of crisis in culture growth.  
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completed. All E6 PHFK cultures showed significantly more anchorage-independent 
survival than PHFKs treated with semisolid medium (p<0.00001). There was a general 
trend of decreased cell death with increasing passage number beginning at passage 16 
among the E6 variants as well as E7 suggesting that the cells were overcoming anoikis 
and were therefore in the beginning stages of becoming transformed (Fig. 8 a). In 
addition, in the absence of growth factors as evidenced during serum starved conditions 
and in the presence of basement membrane proteins which support anchorage, AAE6 
PHFKs were still able to form colonies while this was drastically reduced in HeLa cells 
and little to no colonies were formed by the prototype E6 or L83V PHFKs (Fig. 8 b and 
c). This indicates that the AAE6 variant is more resilient and can survive nutrient poor 
conditions. 
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3.3 Invasion and migration ability is increased in the presence of the E6 oncoprotein.  
 
The initial step in the metastasis cascade is invasion which occurs when the primary 
tumour cells strongly attach to and invade through the epithelial layer into the stroma 
(21). The ability of primary tumour cells to strongly attach, interact and degrade the 
basement membrane proteins is a key process that initiates the metastasis cascade. To 
experimentally mimic these conditions in vitro a cell adhesion assay was initially 
performed to determine the adhesive capability of the E6 PHFKs which is an important 
survival mechanism of the cells to form heterogeneous cell subpopulations that can self-
renew and be chemoresistant. It was observed that all E6 cultures showed a concentration 
dependent increase in adhesion starting from a concentration of 10 µg/mL matrigel (Fig. 
9 a). Interestingly, it was observed that AAE6 had significantly higher adhesion capacity 
compared to prototype E6 and HeLa cells (p<0.05), while all the variants showed 
significantly increased adhesion at 40 µg/mL matrigel concentration compared to control 
PHFKs (p<0.01). It was observed that matrigel did not have a significant effect on the 
cell proliferation or its viability suggesting that the experimental conditions were 
conducive for cell growth (Fig. 9 b). To determine the migratory capability of these cells, 
a Boyden chamber assay was completed using the transduced PHFKs. Keratinocytes 
express collagenase-1 (matrix metalloproteinase 1), a collagen protein degrading enzyme 
necessary for their migration across type 1 collagen, another predominant basement 
membrane protein in the epithelial and endothelial surface (62). It was observed that 
AAE6 PHFKs migrated significantly more than prototype E6 and L83V PHFKs in the 
Boyden chamber (p<0.05) (Fig. 9 c). This trend was also observed in the presence of E7. 
HeLa cells had the highest migration capacity over all variants (p<0.0001). Interestingly, 
PHFKs have a higher migration ability compared to prototype E6, L83V, and E6E7. It is 
expected that the PHFKs have some migratory ability due to the expression of 
collagenase-1 so this may have been interrupted after infection with the oncogenes and 
may be reactivated later in carcinogenesis. One potential mechanism behind migration in 
these keratinocytes is the downregulation of E-cadherin, a cell-cell adhesion molecule. 
To investigate this, western blotting was performed on high passage keratinocytes. It was 
found that the AAE6 variant had lower expression of E-cadherin than the prototype E6 
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 4.0 DISCUSSION 
 
In an effort to examine the carcinogenic potential of three naturally occurring 
HPV 16 E6 gene products, a long-term cell culture study was performed using the E6 
gene variants transduced into their natural keratinocyte host as an experimental model. 
The ability of E6 gene expression to immortalize and transform keratinocytes, and 
thereby increase the ability of the primary keratinocytes to invade and migrate into 
surrounding tissue was investigated. Until now, a similar detailed long term study has 
never been completed. Hence the results from this study fill a large knowledge gap within 
this field of study. Also, through this study a key scientific question about 
immortalization was addressed which began during the late 1980s, when E6 and E7 
oncogenes were first reported to cooperate synergistically to extend primary human 
keratinocytes lifespan (32, 41, 56).  
 
4.1 Extension of Lifespan of the Keratinocyte Model through Infection with E6 
Oncogenes 
 
It is imperative to clarify the role of the E6 oncogene in the cellular 
immortalization process as it is one of the initial steps in the molecular signalling cascade 
that may promote malignancies. Based on a literature analysis, a complete definition of 
immortalization in the keratinocyte model was composed. Appropriate experiments were 
then performed to validate its definition. According to published literature, before cells 
can reach the immortalized state, they must pass through the extension of lifespan stage 
(9). To observe this, PHFKs were transduced with the E6 gene variants or an empty 
vector (pLXSN) as a transduction control. The pLXSN-transduced PHFKs died before 
the normal PHFKs which was probably due to effects from the process of transduction. 
The keratinocytes containing the E6 gene variants were grown up to passage 30, an 
endpoint which was reached fastest by the AAE6 variant over the prototype E6 and L83V 
variants. This was expected, as earlier epidemiological findings have suggested that non-
European variants such as AAE6 are more oncogenic than the E6 prototype based on 
increased prevalence in cervical cancer (5, 95). However, it was unexpected that the 
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prototype E6 reached passage 30 in a shorter amount of time than the L83V variant since 
this amino acid alteration is associated with higher oncogenic potential (2, 95). This could 
change once the cells reach an even higher passage as evidenced by results seen in a 
similar experiment completed by our group (data not published, manuscript submitted) in 
which a different primary keratinocyte donor was used and infected cells were grown 
until passage 60. In this donor, infection with the L83V E6 variant resulted in a shorter 
amount of time to reach passage 60 compared to the prototype E6. So if given enough 
time, the L83V variant in the current study may be able to overtake the prototype E6 
variant. Keratinocytes infected with the E7 oncogene alone have been shown by one 
group (31) to sufficiently immortalize the keratinocytes but this characterization was 
based solely on growth to passage 30 and a visible crisis. In the current study, 
keratinocytes infected with E7 did in fact grow until passage 30 but their initial crisis was 
the longest out of any of the infected cells (about 450 hours, comparable to that of 
PHFKs), and nearing the experimental end-point, the culture exhibited two more very 
long crises (200 and 275 hours). This signifies that the culture was not very resilient and 
suggests that the cells may not have survived in culture if allowed to grow much longer. 
 
4.2 Overcoming M1 and M2 through E6 Oncogene Expression 
 
4.2.1 Functional E6 Oncogenes Allow Keratinocytes to Bypass M1 
Under normal cellular conditions, DNA damage results in activated p53 which in 
turn activates p21. This activation is known to result in downregulation of cyclin-
dependent kinases, consequently leading to G1 arrest (34). Once cells express the E6 
protein and p53 function is abolished, there is no response to DNA damage, and therefore 
no cell cycle arrest (24, 34, 42). Through cell cycle analysis, it was shown that all three 
E6 variants could overcome actinomycin D-induced DNA damage and the resulting G1 
arrest at least as early as passage 6, showing that the E6 oncogene in each of them was 
functional. It has also been shown that in the absence of p53, cells can bypass M1 (88). 
Therefore the presence of the functional E6 oncogene in the PHFKs suggests that the 
cells overcame M1. In cells that express the E7 protein, the interaction between pRb and 
E2F is blocked, leading to a release of E2F transcription factors (34, 77). These activate 
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various E2F-responsive genes that push the cells into S-phase (38), so it is expected that 
the presence of E7 alone should result in the keratinocytes overcoming G1 arrest, which 
was seen once at passage 30. However, because the E7 oncogene does not target p53 
function, the presence of it may not be enough for the cells to overcome M1. In fact, 
Seavey et al. (70) found that E7 actually stabilizes p53, so it is expected that p53-induced 
apoptosis would override any mechanism by which E7 pushes cells past growth arrest. At 
this stage of immortalization, functioning E6 oncogenes can act as both functioning E6 
and E7 oncogenes. Demers et al. (20) showed that functioning p53 can change the 
phosphorylation pattern of pRb to induce growth arrest in cells with damaged DNA. 
Therefore, if p53 function is destroyed by the E6 oncogene it can no longer alter the 
phosphorylation of pRb and cannot induce growth arrest. 
 
4.2.2 Elevated hTERT Levels as Confirmation of Surpassing M2 
An activation of hTERT is one of the defining factors of immortalization. It 
functions in rebuilding the ends of telomeres using its RNA template and reverse 
transcriptase enzyme. Therefore during cellular replication, telomeres are no longer 
constantly shortened, and the cells are not committed to apoptosis (14, 29, 30). It was 
observed that hTERT expression was elevated in all E6 oncogene variants at least as 
early as passage 6 and levels steadily increased as passage number increased. Activation 
of the hTERT gene has been shown to be caused by E6 expression through binding of c-
Myc, another oncoprotein up regulated in many cancers (30, 44, 48, 54, 57, 63, 77, 82, 
89), so it is expected that cells expressing E6 would show activated hTERT. PHFKs 
containing the E7 oncogene did not show any hTERT expression which leads us to the 
conclusion that the E7 oncogene is insufficient for immortalization of PHFKs. 
 
This increase in hTERT expression is known to be directly associated with 
overcoming M2, a point during which telomeres are shortened to a critical length (9, 53, 
66). Another method for overcoming M2 that works in conjuction with increased hTERT 
expression is through p53 degradation. Previous reports have shown that since the E6 
oncoprotein aids in the ubiquitin dependent proteosomal degradation of p53 protein, it 
indirectly results in bypassing the M2 crisis stage (53, 66). Based on the results from this 
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study, it was confirmed that the E6 oncogene can in fact immortalize keratinocytes 
without E7. Moreover, the differences in ability between the gene variants to promote 
immortalization were also characterized and results showed that AAE6 was more 
proficient. These experiments were completed previously by our group (data not 
published, manuscript submitted) with PHFKs from another donor and the results are 
similar to the results seen here, meaning that the effects of the E6 oncogene on PHFKs 
are independent of donor-based lineage. 
 
4.3 Transformation of PHFKs through E6 Oncogene Expression 
 
4.3.1 Anoikis Resistance and Colony Formation as Indicators of Transformation 
Along with immortalization, transformation is another important aspect of the 
carcinogenesis process that was explored in this study. It has been shown that one of the 
main causes of transformation is an up regulation of Notch1 signalling (65) which results 
in resistance to anoikis. Under anoikis-inducing conditions it was found that all E6 
proteins showed increased resistance to anoikis with increasing passages. This is 
expected as E6 induces Notch 1 signalling (84) so it can be assumed that the cells are 
beginning to become transformed. However, compared to untreated controls, cell death 
was still significantly higher even in the E6E7 positive control. Perhaps to significantly 
decrease anoikis, transduced PHFKs must be entirely transformed and contain the 
complete HPV genome. It was observed that PHFKs containing only E7 also exhibited 
some decrease in cell death as passage number increased. This could be caused by its 
interaction with p600, a microtubule protein which has been implicated in deregulating 
anoikis in the presence of the Bovine papillomavirus E7 oncogene (19, 35, 52). 
  
In this study it was found that AAE6-expressing PHFKs showed increased 
potential for transformation (compared to prototype E6 and L83V) through their ability to 
form colony forming units in both anchorage inhibiting and promoting conditions. These 
findings suggest that E6 gene expression is necessary for transformation in vivo and also 
may be important for promoting anchorage to the basement membrane in vivo. In order to 
test this clonogenic assays were performed in serum starved conditions in the presence 
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and absence of basement membrane proteins. The clonogenic assay is an indirect 
qualitative measure to determine the resiliency of the transduced PHFKs in adverse 
conditions. In such culture conditions, the transformed cells should exhibit characteristics 
that are necessary for EMT mediated cancer metastasis, as these types of cells should 
better survive minimalistic culture conditions (46). This could be attributed to the 
modulation of the Wnt/β-catenin signalling pathway (23, 80). For EMT mediated cancer 
metastasis, a sub-population of transformed cells will have to self-renew, be resistant to 
unfavourable growth conditions and be resistant to chemo or radio-therapy (46). It was 
found that when AAE6-expressing PHFKs were grown in serum starved nutrient media 
in absence of basement membrane protein substratum, they resisted apoptosis and 
produced closed cell colonies, suggesting they were capable of surviving inhospitable 
conditions in the human body. This is suggestive of an up-regulation of the Akt signalling 
pathway which is known to have anti-apoptotic functions (76). However, when serum 
starved AAE6-PHFKs were grown in the presence of basement membrane protein 
substratum they formed more mixed colonies that had both closed and scattered colony 
forming units suggesting an adaptable survival mechanism. Once infected keratinocytes 
form colonies, it has been shown that survival in nutrient-poor conditions precedes 
malignant transformation (61); therefore, the continued growth of AAE6 colonies under 
nutrient-poor conditions suggests these cells may be in the early stages of transformation. 
Moreover, AAE6-PHFKs had better adhesion capacity in the presence of basement 
membrane protein, suggesting that this variant has improved anchoring capability which 
might help increase its invasive potential. This concept is supported by the Boyden 
chamber assay results which found that AAE6 was able to migrate through type I 
collagen coated chamber filters significantly more than prototype E6 and L83V.  Some 
groups have shown migration studies involving HPV16 and human umbilical vein 
endothelial cells (64), trophoblastic-like cells (10), cervical keratinocytes (81), or mutant 
keratinocytes (3)1, but the ability of different E6 proteins alone to cause migration and 
invasion in keratinocytes was not examined until now. Although there were marginal 
differences in migratory ability of the E6 variants, the presence of the E6 oncogene did 
not cause the PHFKs to migrate any more than they would normally. Yet for the AAE6 
and L83V variants in the presence of E7, migration was increased and ability to migrate 
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was higher than that of the PHFKs as well as their counterparts containing only the E6 
oncogene. This correlates with results by Charette et al. (13) which suggest that the E7 
oncogene enhances migration in keratinocytes through the Akt signalling pathway. This 
effect was not seen in the prototype E6 variant in the presence of E7, suggesting that 
other pathways or cooperating factors are involved for European variants. 
 
4.4 The E6 Oncogene Variants Activate Expression of Adhesion Molecules at Different 
Levels 
 
During the metastasis stage, a major phenotypic change occurs involving an EMT 
that promotes an invasive and migratory phenotype. One important gene that is down-
regulated during this phase is E-cadherin (85), whose down-regulation permits cells to 
release themselves from each other and prepare for invasion and metastasis (51). In the 
study by Matthews et al. (51), it was found that the E6 oncogene down-regulates E-
cadherin expression, which might partially induce an EMT. However, our results show 
that E-cadherin protein expression is not completely downregulated by the E6 oncogene 
alone which suggests that in the case of HPV16, E7 may be necessary for optimal 
migration. This correlates with the Boyden chamber assay results which show that in the 
presence of E7, the AAE6 variant migrates more than its counterpart containing E6 alone. 
Also, for controls, the decreased level of E-cadherin protein expression directly correlates 
with an increase in migration. The same trend is seen between the E6 variants, with the 
AAE6 showing less E-cadherin protein expression compared to prototype E6 and L83V 
but migrating more. This signifies that E-cadherin protein downregulation may be one 
mechanism that induces migration in the keratinocytes. The downregulated E-cadherin 
expression in PHFKs may be due to the fact that they are primary cells from neonates 
with a mesenchymal phenotype due to retained embryogenesis pathways. The colony 
formation assays also showed no colony formation by PHFKs which could be related to 
this decrease in E-cadherin expression since cell-cell contacts are consequently 
decreased.  
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Another molecule involved in cellular adhesion is CAIX. CAIX is a 
metalloenzyme which is known to function in pH regulation and adhesion (60). Through 
western blotting, it was observed that CAIX protein expression is increased in all variants 
including HeLa cells, but not in PHFKs, and the AAE6 variant has the highest expression 
level over all variants. From the adhesion assay, it was observed that the AAE6 variant 
has increased adhesion capacity which may correlate with the observed increase in CAIX 
expression. The level of CAIX protein expression was also studied in the AAE6 and 
prototype E6 variants in the presence of E7 and it was found to be significantly increased 
in the AAE6/E7 variant over the prototype E6/E7 variant. CAIX is known to be an 
indicator of poor patient prognosis and aggressive tumours in cancers (45, 50) so this 
higher expression in the AAE6 variant may correlate with the increased prevalence of 
this variant in epidemiological studies. HeLa cells showed high CAIX protein expression 
and when this is accompanied by a decrease in E-cadherin protein expression scattered 
colonies can form. This was observed in the colony formation assay and is most likely 
caused by broken cell-cell contact and increased cellular adhesion.  
 
CAIX can be modulated by both hypoxia inducible factor (HIF-1) activation and 
epidermal growth factor receptor (EGFR) (36, 47). Hypoxic tumours have been shown to 
be characteristically more aggressive, lead to a poor response to treatment, and lower 
survival rate (50, 90) due to the up-regulation of HIF-1. Along with increased HIF-1 
expression in cervical cancer (7), multiple studies have found an up-regulation of EGFR 
in cervical cancers (8, 79), so up-regulation of CAIX through either pathway is quite 
plausible. It has been shown that CAIX activation up-regulates the Akt pathway (4, 47, 
76) which leads to anti-apoptotic effects (59), and has been shown to induce cell cycle 
progression through pRb hyperphosphorylation and β-catenin signalling. This also links 
back to activation of the Wnt pathway (59). 
 
One obvious experimental limitation of this study which could affect the observed 
in vitro results is the absence of immune cell factors which may interfere with E6 
promoted cellular activity in vivo. This situation could not be accounted for in the cell 
culture studies. However, our group has extensively discussed the immune response to 
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HPV 16 infection and showed that interferon-kappa (IFN- ), which initiates immune 
response post infection, is down-regulated by E6 expression (17). Another limitation of 
this study that could not be accounted for is the angiogenesis system and associated 
factors that occur in vivo that allow for systemic migration of the infected cells (85). 
Here, E7 might be required for the infected cells to survive the attacks of the immune 
system when they are in systemic blood circulation. However, these aspects were not 
within the scope of the current study which attempted to unravel the effects of E6 alone 
on PHFKs, the primary target of HPV 16 infection.  
 
 5.0 CONCLUSION 
 
Through this study, it was demonstrated that certain naturally occurring E6 
oncogenes that are found in cervical lesions are sufficient to immortalize keratinocytes, 
but only the AAE6 variant was able to transform keratinocytes and increase their 
metastatic potential.  These findings support epidemiological studies showing that the 
incidence of AAE6 in cervical cancers is 20 times higher than other E6 variants or the 
prototype (5). Results from this study suggest that this variant is more likely to survive 
the metastatic cascade and possibly form secondary tumours thus contributing to 
increased oncogenic potential and mortality rates. The results begin to elucidate potential 
pathway activation which may affect the aggressiveness and prevalence of the different 
variants. It seems that CAIX up-regulation is an important factor in the increased 
oncogenic potential of the AAE6 variant.   
 
Although we show the importance of the E6 oncogene, the necessity of the E7 
gene does not go unrecognized, as many of these experiments showed that in the 
presence of E7, the E6 gene function was stabilized and optimal. Also, in the presence of 
E7 the AAE6 variant retained its enhanced oncogenic properties over the prototype E6. 
Clinically, our results suggest that the variable carcinogenic potential and resulting 
prevalence of these different HPV16 subtypes is primarily influenced by the E6 
oncogene, and that the E7 oncogene may be necessary for enhancement of this E6 
function to its full potential. 
51 
 
 
5.1 Future Directions 
 
In light of these findings, the most important next step of this work would be to 
observe the effects of E6 oncogene expression alone in vivo to see the limits of what this 
oncogene can accomplish during the carcinogenic process. Another future step is to 
continue to unlock the pathways that are activated during carcinogenesis by these 
oncogenes and attempt to target them for therapy purposes. A look into HIF-1 or EGFR 
mediated pathways may be the next logical step. Proceeding with in vivo studies in wild-
type and immunocompromised mice would assist in overcoming the limitations of this 
current study. The in vitro model is a controlled environment which can only give results 
suggestive of the in vivo environment so having an in vivo model would allow for the 
effects of angiogenesis pathways on the E6 oncogene function to be observed. 
 
The ability to elucidate the power of a single oncogene, as well as observe the 
difference in power between oncogene variants would provide an extensive base 
knowledge for any future studies involving HPV and cervical cancer. This study may also 
clarify why the non-European variants are more prevalent than the prototype in cervical 
cancers (2, 5, 12, 83, 91, 92, 95). If it was observed that the E6 oncogene can control 
most of the major steps leading to invasive cervical cancer, then more focused therapy 
could be created to block the actual HPV infection from resulting in cancer, or it could be 
used as a druggable target for highly specific antibody or siRNA based therapy. 
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